{
    "nctId": "NCT00198250",
    "briefTitle": "Venlafaxine for Hot Flashes After Breast Cancer",
    "officialTitle": "Venlafaxine for Hot Flashes After Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 75,
    "primaryOutcomeMeasure": "Assess the effectiveness venlafaxine hydrochloride versus placebo in alleviating hot flash frequency, severity, distress, and magnitude in women following treatment for breast cancer.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* women at least 21 years of age\n* willing and able to provide informed consent\n* first time diagnosis of breast cancer\n* no other history of cancer\n* considered disease free at time of study enrollment\n* at least four weeks post-completion of surgery, radiation, and/or chemotherapy for non-metastatic cancer\n* experiencing daily hot flashes\n* desirous of treatment for hot flashes, but not concurrently using any other hot flash treatments\n* living within 60 miles of Indianapolis\n* able to read, write and speak English\n\nExclusion Criteria:\n\n* current treatment with antidepressants for depression, neuropathic pain or hot flashes\n* diagnosis of metastatic breast cancer (stage IV)\n* treatment for hot flashes within the past four weeks, including (a) soy supplements; (b) botanicals, such as dong quai (Angelica sinensis), black cohosh, ginseng, gotu kola, licorice root, chaste tree, sage, or wild yam root; (c) vitamin E; or (d) prescription medications, such as clonidine hydrochloride or megestrol acetate.",
    "sex": "FEMALE",
    "minimumAge": "21 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}